XML 43 R45.htm IDEA: XBRL DOCUMENT v2.4.0.6
ALLIANCES AND COLLABORATIONS (Pfizer) (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Dec. 31, 2011
Alliances and Collaborations Statement [Line Items]          
Net sales $ 3,736 $ 5,345 $ 13,430 $ 15,790  
Deferred income 4,695   4,695   1,203
ELIQUIS [Member]
         
Alliances and Collaborations Statement [Line Items]          
Net sales     1    
Pfizer [Member] | ELIQUIS [Member]
         
Alliances and Collaborations Statement [Line Items]          
Net sales     1    
Percentage reimbursement of development costs from collaboration partner 60.00%   60.00%    
Commercialization expense reimbursements to/(from) Pfizer (6) (2) (14) (5)  
Research and development reimbursements to/(from) collaboration partner (1) (16) 10 (74)  
Amortization income - upfront, milestone and other licensing payments (10) (8) (29) (24)  
Deferred income 405   405   434
Pfizer [Member] | ELIQUIS [Member] | Upfront, milestone and other licensing payments [Member]
         
Alliances and Collaborations Statement [Line Items]          
Total upfront, milestone and other licensing payments $ 559   $ 559